Pharmaceutical Strategy and the Evolving Role of Merger and Acquisition

Thumbnail Image
Penn collection
Health Care Management Papers
Degree type
Health and Medical Administration
Pharmacoeconomics and Pharmaceutical Economics
Pharmacy Administration, Policy and Regulation
Grant number
Copyright date
Related resources
Burns, Lawton R
Nicholson, Sean
Wolkowski, Joanna P

It is not the strongest of the species that survives, nor the most intelligent that survives. It is the one that is the most adaptable to change. Introduction The sections in this chapter deal with a common set of topics: horizontal consolidation, merger and acquisition (M&A), advantages of size, economies of scale and scope, diversification, and industry concentration. These topics all interrelate around the fundamental issue in industrial organization: how best to organize firms and markets in order to achieve optimal economic performance? Consolidation has been rampant in most sectors of the healthcare industry since the 1980s and 1990s. Indeed, the industry was the second most active in terms of M&A activity (behind finance) between 2008 and 2009. In the pharmaceutical sector, the prior decades had been a time of growth and consolidation, as companies leveraged both size and scale in bringing drugs to market. The current landscape, however, is one of new challenges requiring new approaches to their solution. Companies are faced with internal pressures of declining pipeline productivity and compressed timelines, external pressures of patent expiry and pricing, and the uncertain implications of healthcare reform. Accompanying this evolution of challenges has been an evolution in the strategic approaches taken by pharmaceutical companies to best position themselves for success in the upcoming years.

Date Range for Data Collection (Start Date)
Date Range for Data Collection (End Date)
Digital Object Identifier
Book title
Series name and number
Publication date
Volume number
Issue number
Publisher DOI
Journal Issue
Recommended citation